Differential detection of megakaryocytic and erythroid DNA in plasma in hematological disorders.

IF 4.7 2区 医学 Q1 GENETICS & HEREDITY
W K Jacky Lam, Wanxia Gai, Jinyue Bai, Tommy H C Tam, Wai Fung Cheung, Lu Ji, Irene O L Tse, Amy F C Tsang, Maggie Z J Li, Peiyong Jiang, Man Fai Law, Raymond S M Wong, K C Allen Chan, Y M Dennis Lo
{"title":"Differential detection of megakaryocytic and erythroid DNA in plasma in hematological disorders.","authors":"W K Jacky Lam, Wanxia Gai, Jinyue Bai, Tommy H C Tam, Wai Fung Cheung, Lu Ji, Irene O L Tse, Amy F C Tsang, Maggie Z J Li, Peiyong Jiang, Man Fai Law, Raymond S M Wong, K C Allen Chan, Y M Dennis Lo","doi":"10.1038/s41525-024-00423-x","DOIUrl":null,"url":null,"abstract":"<p><p>The tissues of origin of plasma DNA can be revealed by methylation patterns. However, the relative DNA contributions from megakaryocytes and erythroblasts into plasma appeared inconsistent among studies. To shed light into this phenomenon, we developed droplet digital PCR (ddPCR) assays for the differential detection of contributions from these cell types in plasma based on megakaryocyte-specific and erythroblast-specific methylation markers. Megakaryocytic DNA and erythroid DNA contributed a median of 44.2% and 6.2% in healthy individuals, respectively. Patients with idiopathic thrombocytopenic purpura had a significantly higher proportion of megakaryocytic DNA in plasma compared to healthy controls (median: 59.9% versus 44.2%; P = 0.03). Similarly, patients with β-thalassemia were shown to have higher proportions of plasma erythroid DNA compared to healthy controls (median: 50.9% versus 6.2%) (P < 0.0001). Hence, the concurrent analysis of megakaryocytic and erythroid lineage-specific markers could facilitate the dissection of their relative contributions and provide information on patients with hematological disorders.</p>","PeriodicalId":19273,"journal":{"name":"NPJ Genomic Medicine","volume":null,"pages":null},"PeriodicalIF":4.7000,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11300836/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NPJ Genomic Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41525-024-00423-x","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0

Abstract

The tissues of origin of plasma DNA can be revealed by methylation patterns. However, the relative DNA contributions from megakaryocytes and erythroblasts into plasma appeared inconsistent among studies. To shed light into this phenomenon, we developed droplet digital PCR (ddPCR) assays for the differential detection of contributions from these cell types in plasma based on megakaryocyte-specific and erythroblast-specific methylation markers. Megakaryocytic DNA and erythroid DNA contributed a median of 44.2% and 6.2% in healthy individuals, respectively. Patients with idiopathic thrombocytopenic purpura had a significantly higher proportion of megakaryocytic DNA in plasma compared to healthy controls (median: 59.9% versus 44.2%; P = 0.03). Similarly, patients with β-thalassemia were shown to have higher proportions of plasma erythroid DNA compared to healthy controls (median: 50.9% versus 6.2%) (P < 0.0001). Hence, the concurrent analysis of megakaryocytic and erythroid lineage-specific markers could facilitate the dissection of their relative contributions and provide information on patients with hematological disorders.

Abstract Image

血液病患者血浆中巨核细胞和红细胞 DNA 的差异检测。
血浆 DNA 的来源组织可以通过甲基化模式来揭示。然而,巨核细胞和红细胞对血浆 DNA 的相对贡献在不同研究中似乎并不一致。为了揭示这一现象,我们开发了液滴数字 PCR(ddPCR)检测方法,根据巨核细胞特异性和红细胞特异性甲基化标记,对血浆中这些细胞类型的贡献进行差异检测。在健康人中,巨核细胞 DNA 和红细胞 DNA 的贡献率中位数分别为 44.2% 和 6.2%。特发性血小板减少性紫癜患者血浆中巨核细胞DNA的比例明显高于健康对照组(中位数:59.9%对44.2%;P = 0.03)。同样,与健康对照组相比,β-地中海贫血患者血浆中红细胞 DNA 的比例也更高(中位数:50.9% 对 6.2%)(P=0.03)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
NPJ Genomic Medicine
NPJ Genomic Medicine Biochemistry, Genetics and Molecular Biology-Molecular Biology
CiteScore
9.40
自引率
1.90%
发文量
67
审稿时长
17 weeks
期刊介绍: npj Genomic Medicine is an international, peer-reviewed journal dedicated to publishing the most important scientific advances in all aspects of genomics and its application in the practice of medicine. The journal defines genomic medicine as "diagnosis, prognosis, prevention and/or treatment of disease and disorders of the mind and body, using approaches informed or enabled by knowledge of the genome and the molecules it encodes." Relevant and high-impact papers that encompass studies of individuals, families, or populations are considered for publication. An emphasis will include coupling detailed phenotype and genome sequencing information, both enabled by new technologies and informatics, to delineate the underlying aetiology of disease. Clinical recommendations and/or guidelines of how that data should be used in the clinical management of those patients in the study, and others, are also encouraged.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信